ROYALTY PHARMA HOLDINGS LTD
Get an alert when ROYALTY PHARMA HOLDINGS LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
—
Latest balance sheet
Net assets
—
Equity attributable
Employees
—
Average over period
Profit before tax
£1.2B
USD 1,624,044,000
+22.5% vs 2024
Net assets
3-year trend · vs Consumer Discretionary median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | — | — | — | — | |
| Operating profit | — | £1,161,209,762 | £1,446,116,185 | +24.5% | |
| Profit before tax | £1,318,591,106 | £992,391,077 | £1,215,783,800 | +22.5% | |
| Net profit | £1,318,591,106 | £990,256,026 | £1,215,708,938 | +22.8% | |
| Cash | £29,193,742 | £37,900,883 | — | — | |
| Total assets less current liabilities | £11,098,398,712 | £11,803,789,489 | — | — | |
| Net assets | £6,506,107,202 | £6,852,638,868 | — | — | |
| Equity | £6,506,107,202 | £6,852,638,868 | — | — | |
| Average employees | — | — | — | — | |
| Wages | — | — | — | — | |
| Directors' remuneration | £0 | £0 | — | — |
Figures converted to GBP from USD at 0.749 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Return on capital employed | — | 9.8% | — | |
| Gearing (liabilities / total assets) | 41.6% | 46.1% | — | |
| Current ratio | 0.78x | 0.04x | — | |
| Interest cover | — | 6.88x | 6.28x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young Chartered Accountants
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“After reviewing the Company's performance projections, the directors are satisfied that the Company has adequate access to resources to enable it to meet its obligations and to continue in operational existence for the foreseeable future. As a result, they have adopted the going concern basis in preparing the financial statements.”
Group structure
- ROYALTY PHARMA HOLDINGS LTD · parent
- Royalty Pharma Investments 2019 ICAV 100%
- Royalty Pharma Development Funding, LLC 100%
- Royalty Pharma Finance Corporation 100%
- Royalty Pharma Investments 2023 ICAV 100%
- RPI 2019 Intermediate Finance Trust 100%
- ImmuNext, LLC 100%
- Royalty Pharma Manager, LLC 100%
- Royalty Pharma Sub-Manager, LLC 100%
- Royalty Pharma, LLC 100%
- Royalty Pharma Sub-Manager A, LLC 100%
- Royalty Pharma Investments ICAV 82.42%
- RPI Acquisitions (Ireland) Limited 82.42%
- Royalty Pharma Investments 2011 ICAV 82.42%
- RPI Finance Trust 82.42%
- Royalty Pharma Collection Trust 85.94%
- RP IP HoldCo (Ireland) Limited 85.94%
Significant events
- “On January 1, 2026, Arthur McGivern was appointed to the board of directors of the Company.”
- “On March 3, 2026, the Company's board of directors approved an interim dividend of $0.235 per Class A and Class B ordinary share, which was paid on March 3, 2026.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 2 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| COYNE, Terrance | Director | 2020-06-10 | Feb 1982 | American |
| LEGORRETA, Pablo | Director | 2020-02-10 | Oct 1963 | American |
| MCGIVERN, Arthur | Director | 2026-01-01 | Aug 1975 | American |
Show 2 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| VISTRA COSEC LIMITED | Corporate Secretary | 2020-02-10 | 2020-06-05 |
| LLOYD, George Wingate | Director | 2020-06-10 | 2025-12-31 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Royalty Pharma Plc | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2020-02-10 | Active |
Filing timeline
Last 20 of 110 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-07-01 | SH08 | capital | Capital name of class of shares | |
| 2026-06-21 | AA | accounts | Accounts with accounts type full | |
| 2026-06-19 | SH01 | capital | Capital allotment shares | |
| 2026-06-18 | SH08 | capital | Capital name of class of shares | |
| 2026-06-03 | SH01 | capital | Capital allotment shares | |
| 2026-05-08 | SH01 | capital | Capital allotment shares | |
| 2026-05-08 | SH01 | capital | Capital allotment shares | |
| 2026-05-08 | SH01 | capital | Capital allotment shares | |
| 2026-05-08 | SH08 | capital | Capital name of class of shares | |
| 2026-05-01 | SH08 | capital | Capital name of class of shares | |
| 2026-03-03 | SH08 | capital | Capital name of class of shares | |
| 2026-02-23 | SH01 | capital | Capital allotment shares | |
| 2026-02-21 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2026-01-20 | SH01 | capital | Capital allotment shares | |
| 2026-01-16 | TM01 | officers | Termination director company with name termination date | |
| 2026-01-16 | AP01 | officers | Appoint person director company with name date | |
| 2026-01-06 | SH01 | capital | Capital allotment shares | |
| 2026-01-06 | SH01 | capital | Capital allotment shares | |
| 2025-12-29 | SH01 | capital | Capital allotment shares | |
| 2025-12-29 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 20
- Capital events
- 16
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.